

## ARG83054 Human SARS-CoV-2 IgA antibody ELISA Kit

Package: 96 wells Store at: 4°C

# Summary

Product Description	ARG83054 Human SARS-CoV-2 IgA antibody ELISA Kit is an enzyme immunoassay kit for the qualitative of SARS-CoV-2 IgA antibody in Human serum and plasma (EDTA, heparin, citrate)
Tested Reactivity	Hu
Tested Application	ELISA
Target Name	Human SARS-CoV-2 IgA
Conjugation	HRP
Conjugation Note	Substrate: TMB and read at 450 nm.
Sensitivity	diagn. 100 %
Detection Range	Cut - off
Sample Type	serum, plasma (citrate, heparin)
Sample Volume	100 μΙ
Precision	Intra-Assay CV: less than 8% Inter-Assay CV: less than 7%
Alternate Names	SARS-CoV

### **Application Instructions**

Assay Time

~2 hour

#### Properties

Form	96 well
Storage instruction	Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components.
Note	For laboratory research only, not for drug, diagnostic or other use.

### Bioinformation

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARSECOVE2) is a strain of coronavirus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus previously had a provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called the human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a public health emergency of international concern on January 30, 2020, and a pandemic on March 11, 2020. SARSECoVE2 is a positive-sense single-stranded RNA virus that is contagious in humans.HighlightRelated products: SARS-CoV antibodies; SARS-CoV ELISA Kits; SARS-CoV recombinant proteins; Anti-Human IgG
COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus previously had a provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called the human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a public health emergency of international concern on January 30, 2020, and a pandemic on March 11, 2020. SARS@CoV@2 is a

secondary antibodies: Related news: HMGB1, a biomarker and therapeutic target in COVID-19 Exploring Antiviral Immune Response